Indrayani Biotech: Audited FY26 Results Approved, Net Profit Stands at ₹216.03 Lakhs

Indrayani Biotech Limited has announced the approval of its audited financial results for the fiscal year ended March 31, 2026. The consolidated net profit after tax for the year stood at ₹216.03 lakhs. The Board of Directors reviewed and approved these results, which have been subjected to audit by the statutory auditors. The financial statements reflect the company’s performance and comprehensive income for the period.

Indrayani Biotech Approves Audited Financial Results

Indrayani Biotech Limited has officially announced the approval of its audited financial results for the fiscal year ending March 31, 2026. This significant corporate action was taken at the Board of Directors’ meeting held on August 17, 2026.

Key Financial Highlights

The audited consolidated financial results for the year ended March 31, 2026, reveal a net profit after tax of ₹216.03 lakhs. The company’s total comprehensive income for the period was ₹216.81 lakhs. These figures reflect the overall financial performance and include adjustments for various income and expense items, as well as other comprehensive income.

Consolidated Performance Overview

The consolidated statement of profit and loss shows revenue from operations amounting to ₹13,783.12 lakhs for the year ended March 31, 2026, compared to ₹13,022.84 lakhs in the previous year. Total expenses were ₹14,210.36 lakhs. The company reported earnings per share (basic and diluted) of ₹0.48 for the full year.

Standalone Financials

In addition to the consolidated results, Indrayani Biotech also presented its standalone financial results. For the standalone entity, the profit for the period was ₹69.97 lakhs, with total comprehensive income at ₹69.97 lakhs. The standalone earnings per share (basic and diluted) stood at ₹0.15.

Audit and Disclosure

The financial results have been audited by Venkatesh & Co, Chartered Accountants. The auditors have provided a qualified opinion, noting certain limitations in their audit scope, particularly concerning specific loan, asset, and receivable balances. The company has made these financial results available on its website and with the Bombay Stock Exchange.

Source: BSE

Previous Article

Lloyds Metals and Energy: Q1 FY27 Sees Record Revenue of ₹7,354 Cr & 39.2% EBITDA Margin

Next Article

Indrayani Biotech: Approves Audited FY26 Financial Results